These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Platelet transfusion refractoriness responding preferentially to single donor aphaeresis platelets compatible for both ABO and HLA. McVey M; Cserti-Gazdewich CM Transfus Med; 2010 Oct; 20(5):346-53. PubMed ID: 20492602 [TBL] [Abstract][Full Text] [Related]
4. Determination Thuku NW; Shikuku K; Mbugua A Pan Afr Med J; 2017; 27():226. PubMed ID: 28979628 [TBL] [Abstract][Full Text] [Related]
5. Prevention and management of platelet transfusion refractoriness. Novotny VM Vox Sang; 1999; 76(1):1-13. PubMed ID: 9933848 [TBL] [Abstract][Full Text] [Related]
6. Recognition and management of antibodies to human platelet antigens in platelet transfusion-refractory patients. Vassallo RR Immunohematology; 2009; 25(3):119-24. PubMed ID: 20406018 [TBL] [Abstract][Full Text] [Related]
7. [Transfusion of platelet concentrates]. Rieux C; Lee K; Lavaud A; Bierling P Ann Med Interne (Paris); 1999 Dec; 150(8):631-41. PubMed ID: 10686645 [TBL] [Abstract][Full Text] [Related]
8. Analysis of platelet-reactive alloantibodies and evaluation of cross-match-compatible platelets for the management of patients with transfusion refractoriness. Wang J; Xia W; Deng J; Xu X; Shao Y; Ding H; Chen Y; Liu J; Chen D; Ye X; Santoso S Transfus Med; 2018 Feb; 28(1):40-46. PubMed ID: 28516675 [TBL] [Abstract][Full Text] [Related]
9. Platelet transfusion refractoriness: how do I diagnose and manage? Cohn CS Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):527-532. PubMed ID: 33275694 [TBL] [Abstract][Full Text] [Related]
11. Antibodies to human platelet antigens form a significant proportion of platelet antibodies detected in Indian patients with refractoriness to platelet transfusions. Abraham AS; Chacko MP; Fouzia NA; Srivastava A; Daniel D Transfus Med; 2018 Oct; 28(5):392-397. PubMed ID: 29460307 [TBL] [Abstract][Full Text] [Related]
12. Management of the Platelet Refractory Patient. Forest SK; Hod EA Hematol Oncol Clin North Am; 2016 Jun; 30(3):665-77. PubMed ID: 27113003 [TBL] [Abstract][Full Text] [Related]
13. How do I … manage the platelet transfusion-refractory patient? Juskewitch JE; Norgan AP; De Goey SR; Duellman PM; Wakefield LL; Gandhi MJ; Stubbs JR; Kreuter JD Transfusion; 2017 Dec; 57(12):2828-2835. PubMed ID: 28960321 [TBL] [Abstract][Full Text] [Related]
14. Pathogen-reduced platelets for the prevention of bleeding. Butler C; Doree C; Estcourt LJ; Trivella M; Hopewell S; Brunskill SJ; Stanworth S; Murphy MF Cochrane Database Syst Rev; 2013 Mar; (3):CD009072. PubMed ID: 23543569 [TBL] [Abstract][Full Text] [Related]
15. Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity. Petz LD; Garratty G; Calhoun L; Clark BD; Terasaki PI; Gresens C; Gornbein JA; Landaw EM; Smith R; Cecka JM Transfusion; 2000 Dec; 40(12):1446-56. PubMed ID: 11134563 [TBL] [Abstract][Full Text] [Related]
16. A mini-review on platelet refractoriness. Rebulla P Haematologica; 2005 Feb; 90(2):247-53. PubMed ID: 15710579 [TBL] [Abstract][Full Text] [Related]
17. Refractoriness to platelet transfusion. Rebulla P Curr Opin Hematol; 2002 Nov; 9(6):516-20. PubMed ID: 12394175 [TBL] [Abstract][Full Text] [Related]